electroCore, Inc.ECOREarnings & Financial Report
electroCore, Inc. is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The current chief executive officer is Daniel S. Goldberger. electroCore has one product called gammaCore, a non-invasive, commercially available product that uses vagus nerve stimulation.
ECOR Q4 FY2025 Key Financial Metrics
Revenue
$9.2M
Gross Profit
$8.2M
Operating Profit
$-2.9M
Net Profit
$-3.0M
Gross Margin
88.4%
Operating Margin
-31.8%
Net Margin
-32.8%
YoY Growth
31.2%
EPS
$-0.34
electroCore, Inc. Q4 FY2025 Financial Summary
electroCore, Inc. reported revenue of $9.2M (up 31.2% YoY) for Q4 FY2025, with a net profit of $-3.0M (up 6.0% YoY) (-32.8% margin). Cost of goods sold was $1.1M, operating expenses totaled $11.1M.
Key Financial Metrics
| Total Revenue | $9.2M |
|---|---|
| Net Profit | $-3.0M |
| Gross Margin | 88.4% |
| Operating Margin | -31.8% |
| Report Period | Q4 FY2025 |
electroCore, Inc. Annual Revenue by Year
electroCore, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $32.0M).
electroCore, Inc. Quarterly Revenue & Net Profit History
electroCore, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $9.2M | +31.2% | $-3.0M | -32.8% |
| Q3 FY2025 | $8.7M | +32.6% | $-3.4M | -39.2% |
| Q2 FY2025 | $7.4M | +20.2% | $-3.7M | -49.7% |
| Q1 FY2025 | $6.7M | +23.4% | $-3.9M | -57.4% |
| Q4 FY2024 | $7.0M | +35.7% | $-3.2M | -45.8% |
| Q3 FY2024 | $6.6M | +45.4% | $-2.5M | -38.1% |
| Q2 FY2024 | $6.1M | +72.9% | $-2.7M | -43.2% |
| Q1 FY2024 | $5.4M | +95.8% | $-3.5M | -64.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $6.1M | $6.6M | $7.0M | $6.7M | $7.4M | $8.7M | $9.2M |
| YoY Growth | 95.8% | 72.9% | 45.4% | 35.7% | 23.4% | 20.2% | 32.6% | 31.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.9M | $22.4M | $21.0M | $20.5M | $16.0M | $14.6M | $21.4M | $18.7M |
| Liabilities | $9.4M | $10.9M | $11.6M | $12.9M | $11.7M | $13.4M | $22.5M | $20.4M |
| Equity | $4.5M | $11.5M | $9.5M | $7.5M | $4.4M | $1.1M | $-1.1M | $-1.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.6M | $-1.8M | $-1.4M | $-1.3M | $-4.4M | $-623000 | $-1.7M | $-1.5M |